Information Provided By:
Fly News Breaks for February 24, 2017
BSX
Feb 24, 2017 | 07:57 EDT
Leerink analyst Danielle Antalffy believes the selloff in Boston Scientific's shares was "overdone" and would recommend buying on weakness following the announcement of a Lotus recall in Europe and 2-quarter delay in U.S. PMA filing/approval. The analyst believes the impact from the Lotus recall is limited, and reiterates an Outperform rating on the shares.
News For BSX From the Last 2 Days
BSX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.